Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23953078 | 0.94 | TYMP (0.41) | TYMPP2RY12P2RY1ADORA3ADORA2B | |
| SCHEMBL24354783 | 0.92 | TYMP (0.39) | TYMPP2RY12P2RY1ADORA3ADORA2B | |
| SCHEMBL24354796 | 0.90 | TYMP (0.36) | TYMPP2RY12P2RY1ADORA3ADORA2B | |
| SCHEMBL23953080 | 0.90 | TYMP (0.36) | TYMPP2RY12P2RY1ADORA3ADORA2B | |
| SCHEMBL24354787 | 0.89 | P2RY12 (0.39) | P2RY12P2RY1 | |
| SCHEMBL24354785 | 0.89 | P2RY12 (0.38) | P2RY12P2RY1ADORA3ADORA2BADORA1 | |
| SCHEMBL23953082 | 0.85 | P2RY1 (0.46) | TYMPP2RY12P2RY1ADORA3ADORA2B | |
| SCHEMBL4345769 | 0.84 | TYMP (0.38) | TYMPP2RY12ADORA3ADORA2BADORA1 | |
| SCHEMBL4345765 | 0.84 | TYMP (0.38) | TYMPP2RY12ADORA3ADORA2BADORA1 | |
| SCHEMBL24354797 | 0.82 | TYMP (0.38) | TYMPP2RY12P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125821-A1 | CYCLIC DINUCLEOTIDE PRODRUG MOLECULE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN YING BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125821-A1 | CYCLIC DINUCLEOTIDE PRODRUG MOLECULE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | DPYD, PDE11A, PDE7A | TYMP 4/4885P2RY12 389/4885P2RY1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.